Vanguard Global Advisers’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
Other funds holding DNTH
Vanguard Global Advisers's DNTH Position: Q3 2026 in Review
Vanguard Global Advisers increased its Dianthus Therapeutics (DNTH) stake by 31% in Q3 2026, buying an estimated $624K and bringing the position to 25,575 shares worth $2.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1169.
Vanguard Global Advisers first reported a position in DNTH in Q1 2026 and has held it in 3 quarters since. 272 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.
- Vanguard Global Advisers held 25,575 shares of Dianthus Therapeutics worth $2.25M as of Q3 2026.
- Vanguard Global Advisers bought 6,011 Dianthus Therapeutics shares in Q3 2026, an estimated $624K.
- Dianthus Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1169 holding.
- Vanguard Global Advisers first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 272 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.